Cabaletta Bio reports a $53.1 million third-quarter loss

Cabaletta Bio reported a third-quarter 2026 net loss of $53.1 million and cash, cash equivalents and short-term investments of $299.4 million as of September 30. The company said its cash position is expected to fund operations into the first quarter of 2028. It also outlined clinical program miles…